Imfinzi (durvalumab) Receives Positive CHMP Opinion in EU for PD-L1 expressing LA NSCLC patients

 Imfinzi (durvalumab) Receives Positive CHMP Opinion in EU for PD-L1 expressing LA NSCLC patients

Imfinzi (durvalumab) Receives Positive CHMP Opinion in EU for PD-L1 expressing LA NSCLC patients

Shots:
  •  Imfinzi has been approved in unresectable PD-L1 expressing LA NSCLC patients treated with platinum-based CRT
  • Approval is based post-hoc subgroup analyses by PD-L1 expression in addition to PFS & OS results of PACIFIC trial
  • In 2018, AZ received recommendations for Stage III NSCLC US, Canada, Switzerland, India, and Japan based on PACIFIC trial

Click here to read full press release/ article | Ref: Astrazeneca | Image: Bloomberg

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post